Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCD | Q05655 | 7/20 | 0.88 |
| ▸ | PRKACA | P17612 | 6/20 | 0.88 |
| ▸ | PRKD3 | O94806 | 6/20 | 0.88 |
| ▸ | PRKCZ | Q05513 | 6/20 | 0.88 |
| ▸ | PRKACG | P22612 | 5/20 | 0.88 |
| ▸ | PRKACB | P22694 | 5/20 | 0.88 |
| ▸ | PRKCG | P05129 | 5/20 | 0.88 |
| ▸ | PRKCB | P05771 | 5/20 | 0.88 |
| ▸ | PRKCA | P17252 | 5/20 | 0.88 |
| ▸ | PRKCH | P24723 | 5/20 | 0.88 |
| ▸ | PRKCI | P41743 | 5/20 | 0.88 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.88 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.88 |
| ▸ | PRKD1 | Q15139 | 5/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.88 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.88 |
| ▸ | MEN1 | O00255 | 2/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.88 |
| ▸ | HTT | P42858 | 2/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30439885 | 1.00 | PRKCD (0.88) | PRKCDPRKACAPRKD3PRKCZPRKACG | |
| SCHEMBL2456849 | 1.00 | PRKCD (0.88) | PRKCDPRKACAPRKD3PRKCZPRKACG | |
| SCHEMBL13186226 | 1.00 | PRKCD (0.88) | PRKCDPRKACAPRKD3PRKCZPRKACG | |
| SCHEMBL30439349 | 1.00 | PRKCD (0.88) | PRKCDPRKACAPRKD3PRKCZPRKACG | |
| Hydrochloric Acid SCHEMBL30439093 | 0.99 | PRKCD (0.88) | PRKCDPRKACAPRKD3PRKCZPRKACG | |
| Hydrochloric Acid SCHEMBL23795350 | 0.99 | PRKCD (0.88) | PRKCDPRKACAPRKD3PRKCZPRKACG | |
| Hydrochloric Acid SCHEMBL30439330 | 0.99 | PRKCD (0.88) | PRKCDPRKACAPRKD3PRKCZPRKACG | |
| Hydrochloric Acid SCHEMBL23795291 | 0.99 | PRKCD (0.88) | PRKCDPRKACAPRKD3PRKCZPRKACG | |
| SCHEMBL13186232 | 0.97 | PRKCD (0.86) | PRKCDPRKACAPRKD3PRKCZPRKACG | |
| SCHEMBL190590 | 0.93 | PRKCD (1.00) | PRKCDPRKACAPRKD3PRKCZPRKACG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002265-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) | 2022-01-06 | — | — | US | claimed |
| EP-3878846-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | Beijing Increase Innovative Drug Co., Ltd. (CN) | 2021-09-15 | — | — | EP | claimed |
| CN-111116555-A | Rho kinase inhibitor and preparation method and application thereof | 北京盈科瑞创新药物研究有限公司 | 2020-05-08 | — | — | CN | claimed |
| US-12264146-B2 | Rho kinase inhibitor, method for preparing same and uses thereof | BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) | 2025-04-01 | — | — | US | disclosed |
| CN-111116555-B | Rho kinase inhibitor and preparation method and application thereof | 北京盈科瑞创新药物研究有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20220002265-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) | 2022-01-06 | — | — | US | disclosed |
| US-20220002265-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) | 2022-01-06 | — | — | US | disclosed |
| EP-3878846-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | Beijing Increase Innovative Drug Co., Ltd. (CN) | 2021-09-15 | — | — | EP | disclosed |
| CN-111116555-A | Rho kinase inhibitor and preparation method and application thereof | 北京盈科瑞创新药物研究有限公司 | 2020-05-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002265-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | ROCK1, RHOA, ROCK2 | PRKCD 517/4885PRKACA 288/4885PRKD3 399/4885 |
| US-12264146-B2 | Rho kinase inhibitor, method for preparing same and uses thereof | ROCK1, RHOA, ROCK2 | PRKCD 517/4885PRKACA 288/4885PRKD3 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.